Stay updated with breaking news from High Acuity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Truist Financial downgraded shares of Amedisys (NASDAQ:AMED – Get Rating) from a buy rating to a hold rating in a research report report published on Wednesday morning, The Fly reports. Truist Financial currently has $97.00 price objective on the health services provider’s stock. Several other research firms have also recently weighed in on AMED. Barclays […]
Credit Suisse Group cut shares of Amedisys (NASDAQ:AMED – Get Rating) from an outperform rating to a neutral rating in a research note released on Tuesday morning, The Fly reports. A number of other research analysts have also recently weighed in on AMED. Benchmark restated a buy rating and issued a $115.00 price target on […]
Credit Suisse Group lowered shares of Amedisys (NASDAQ:AMED – Get Rating) from an outperform rating to a neutral rating in a research note published on Tuesday, The Fly reports. Several other research analysts also recently commented on AMED. Truist Financial cut their target price on Amedisys from $115.00 to $97.00 in a research note on […]
ExodusPoint Capital Management LP acquired a new stake in Amedisys, Inc. (NASDAQ:AMED – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 29,683 shares of the health services provider’s stock, valued at approximately $2,480,000. ExodusPoint Capital Management LP owned about 0.09% of […]
StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED – Get Rating) in a research note published on Thursday. The firm issued a buy rating on the health services provider’s stock. A number of other research analysts have also issued reports on AMED. Barclays cut their price target on shares of Amedisys from $93.00 to $88.00 […]